BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

INCY upcoming catalysts

Incyte Corporation: 3 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (1 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 18 readout(s) and 4 FDA event(s). Subscribe to INCY (.ics).

Drugs: Povorcitinib, Ruxolitinib, INCB099280, Lenalidomide, Cyclophosphamide, Doxorubicin, Prednisone, ICS-LABA, INCA034176, ibrutinib, Axatilimab, Corticosteroids, Rituximab, Vincristine, Retifanlimab, Dexamethasone, Methotrexate, Osimertinib

Upcoming FDA decision events

DateEventStatusCompanyDrugSource
No upcoming PDUFA date or AdCom found.

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-20 est.P2Incyte Corporation INCYNCT05851443 A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe AsthmaModerate to Severe Asthmaactive not recruiting247
2026-12-26 est.P3Incyte Corporation INCYNCT06212999 A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis SuppurativaHidradenitis Suppurativa (HS)active not recruiting617
2027-01-06 est.P1/P2Incyte Corporation INCYNCT06843408 A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHDChronic Graft-versus-host-diseaseactive not recruiting32

FDA decision events, last 12 months

DateEventStatusCompanyDrugSource
2026-05-18FDA approvalapprovedINCYTE CORP INCYZYNYZApproved 2026-05-18: ZYNYZ (BLA761334 SUPPL9)
2026-05-01FDA approvalapprovedINCYTE CORP INCYJAKAFIApproved 2026-05-01: JAKAFI XR (NDA217180 ORIG1)
2026-03-30FDA approvalapprovedINCYTE CORP INCYZYNYZApproved 2026-03-30: ZYNYZ (BLA761334 SUPPL8)
2025-12-17FDA approvalapprovedINCYTE CORP INCYZYNYZApproved 2025-12-17: ZYNYZ (BLA761334 SUPPL5)

Trial readouts, last 12 months

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-05 est.P2Incyte Corporation INCYNCT04509700 Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)B-Cell Malignanciesactive not recruiting112
2026-10-29P3Incyte Corporation INCYNCT06959225 Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)Hidradenitis Suppurativaactive not recruiting580
2026-10-19 est.P3Incyte Corporation INCYNCT06516952 A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)Prurigo Nodularisactive not recruiting349
2026-10-01P3Incyte Corporation INCYNCT06958211 Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)Hidradenitis Suppurativaactive not recruiting573
2026-10-01P2Incyte Corporation INCYNCT06388564 A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host DiseaseChronic Graft-versus-host-diseaseactive not recruiting130
2026-09-30P2Incyte Corporation INCYNCT05879822 A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor NaiveAdvanced Solid Tumorterminated73
2026-09-28P3Incyte Corporation INCYNCT06516965 A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)Prurigo Nodularisactive not recruiting346
2026-09-28P2Incyte Corporation INCYNCT05888844 A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell CarcinomaCutaneous Squamous Cell Carcinomaterminated63
2026-09-01 est.P3Incyte Corporation INCYNCT04824092 Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL PatientsDiffuse Large B-cell Lymphomaactive not recruiting899
2026-08-07P3Incyte Corporation INCYNCT06832618 A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic DermatitisAtopic Dermatitisactive not recruiting159
2026-07-29P1/P2Incyte Corporation INCYNCT06873789 A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid TumorsSolid Tumors; Advanced Solid Tumors; Metastatic Solid Tumorsterminated9
2026-05-29P2Incyte Corporation INCYNCT04463771 Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer WhEndometrial Cancercompleted206
2026-05-11P2Incyte Corporation INCYNCT04640025 A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of ItacitinibMyelofibrosis; Postlung Transplant (Bronchiolitis Obliterans); Chronic Graft Versus Host Diseaseterminated18
2026-03-30P3Incyte Corporation INCYNCT05429268 Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)Large B-Cell Lymphoma; Diffuse Large B-Cell Lymphomaactive not recruiting82
2026-03-17P3Incyte Corporation INCYNCT06113471 A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)NonSegmental Vitiligoactive not recruiting450
2026-03-03P2Incyte Corporation INCYNCT02723994 A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic LeukemiaLeukemiacompleted171
2026-02-24P3Incyte Corporation INCYNCT06113445 A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)NonSegmental Vitiligoactive not recruiting467
2025-12-24P1/P2Incyte Corporation INCYNCT02917993 An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung CancerLung Cancercompleted59

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.